Aaron Trimble

Aaron Trimble

Auto-generated profile, based on publicly available information

Aaron Trimble

Division of Pulmonary Allergy, and Critical Care Medicine Oregon Health & Science University Portland Oregon USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
ATAaron Trimble
Aaron Trimble
CMCameron McKinzie
Cameron McKinzie
MTMary Terrell
Mary Terrell
ESElizabeth Stringer
Elizabeth Stringer
CECharles R. Esther
Charles R. Esther

22 December 2021 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
BCBethany Collins
Bethany Collins
CFChristopher Fortner
Christopher Fortner
ACAmanda Cotey
Amanda Cotey
CECharles R. Jr Esther
Charles R. Jr Esther
ATAaron Trimble
Aaron Trimble

1 March 2018 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
ATAaron T. Trimble
Aaron T. Trimble
SDScott H. Donaldson
Scott H. Donaldson

1 September 2018 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
ATAaron T. Trimble
Aaron T. Trimble
ABA. Whitney Brown
A. Whitney Brown
BLBeth L. Laube
Beth L. Laube
NLNoah Lechtzin
Noah Lechtzin
KZKirby L. Zeman
Kirby L. Zeman
SDScott H. Donaldson
Scott H. Donaldson

30 January 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JGJennifer L Goralski
Jennifer L Goralski
SCSang Hun Chung
Sang Hun Chung
TGTyler M. Glass
Tyler M. Glass
ACAgathe S. Ceppe
Agathe S. Ceppe
EAEsther O. Akinnagbe-Zusterzeel
Esther O. Akinnagbe-Zusterzeel
YLYueh Z Lee
Yueh Z Lee
We hypothesized that dynamic perfluorinated gas MRI would sensitively detect mild cystic fibrosis (CF) lung disease. This cross-sectional study enrolled 20 healthy volunteers and 24 stable subjects with CF, including a subgroup of subjects with normal forced expiratory volume in the first second (FEV 1 ; >80% predicted, n = 9). Dynamic fluorine-19–enhanced MRI ( 19 F MRI) were acquired during sequential breath holds while breathing perfluoropropane (PFP) and during gas wash-out. Outcomes included the fraction of lung without significant ventilation (ventilation defect percent, VDP) and time constants that described PFP wash-in and wash-out kinetics. VDP values (mean ± SD) of healthy controls (3.87% ± 2.7%) were statistically different from moderate CF subjects (19.5% ± 15.5%, P = 0.001) but not from mild CF subjects (10.4% ± 9.9%, P = 0.24). In contrast, the fractional lung volume with slow gas wash-out was elevated both in subjects with mild (9.61% ± 4.87%; P = 0.0066) and moderate CF (16.01% ± 5.01%; P = 0.0002) when compared with healthy controls (3.84% ± 2.16%) and distinguished mild from moderate CF ( P = 0.006). 19 F MRI detected significant ventilation abnormalities in subjects with CF. The ability of gas wash-out kinetics to distinguish between healthy and mild CF lung disease subjects makes 19 F MRI a potentially valuable method for the characterization of early lung disease in CF. This study has been registered at ClinicalTrials.gov (NCT03489590).

5 August 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
SSSylvia Szentpetery
Sylvia Szentpetery
DRDara Riva
Dara Riva
YBYair J. Blumenfeld
Yair J. Blumenfeld
JEJohn F. Engelhardt
John F. Engelhardt
CLCarmen Luna-Paredes
Carmen Luna-Paredes
Jennifer L TaylorJennifer L Taylor
Jennifer L Taylor
Data from cystic fibrosis (CF) animal models and case studies suggests that in utero administration of CF transmembrane conductance regulator (CFTR) modulators (variant specific therapies, VST) can rescue CFTR-related pathophysiology in the fetus. Use of VST during pregnancy to prevent disease in infants has not been systematically studied. Through stakeholder engagement, we sought to determine if formal research evaluation is warranted. We surveyed CF care center directors to assess their awareness of the potential off-label use of VST for in utero treatment of a fetus with CF. We then conducted a one-day, international multidisciplinary workshop to review available pre-clinical and clinical data, embryology principles and federal drug regulation considerations, identify knowledge gaps, and consider future clinical study designs. Sixty-two unique individuals responded to the survey; 92% were aware of use of VST to treat pregnant females who are CF carriers for the prevention of CF complications in the fetus. Expert workshop presentations suggested that use of VST in pregnant females carrying a fetus with CF to mitigate complications of CF is relatively safe and effective in animal models and human case series to date. Further research is needed to understand the optimal timing of VST initiation during pregnancy to improve clinical outcomes, to understand VST pharmacokinetics, and optimize dosing of VST during pregnancy and lactation, and to evaluate the long-term infant safety among those exposed to VST in utero. Based on available data and knowledge gaps, stakeholders agreed that formal evaluation of in utero and early life VST therapy in a prospective trial is warranted.